3D bioprinting is an advanced biotechnology that enables the fabrication of three-dimensional tissue constructs using living cells and specialized biomaterials known as bioinks. It is one of the foundational technologies driving modern tissue engineering, regenerative medicine, and biofabrication.

Biofabrication is an interdisciplinary field that integrates cell biology, materials engineering, and additive manufacturing technologies to produce biologically functional structures. It encompasses 3D bioprinting, biomaterials design, and controlled engineering of the cellular microenvironment.

3D bioprinting technology relies on the layer-by-layer deposition of biocompatible, cell-laden materials, enabling the recreation of tissue architecture and biological microenvironments. As a result, highly representative in vitro tissue models can be produced for biomedical research and the development of advanced therapies.

3D bioprinting is an additive manufacturing process in which bioinks containing living cells are precisely deposited under controlled laboratory conditions. The goal is to fabricate structures that replicate the architecture and function of complex biological tissues in vitro.

Unlike traditional 2D cell cultures, 3D-bioprinted tissue models more accurately reproduce the cellular microenvironment. Cells behave in a manner that closely resembles physiological conditions — both in spatial organization and biological activity.

The foundations of 3D printing date back to the 1980s, when Charles Hull developed stereolithography (1984), the first commercial 3D printing method. The origins of bioprinting are traced to 1988, when Robert J. Klebe first used a modified inkjet printer to deposit living cells.

Since then, advances in biomaterials, bioinks, and precision printing systems have enabled the fabrication of increasingly complex tissue constructs.

Today, 3D bioprinting represents one of the most dynamic and strategically important areas of biotechnology, accelerating progress in regenerative medicine, tissue engineering, and Advanced Therapy Medicinal Products (ATMPs).

3D bioprinting enables the replication of human tissue microenvironments under in vitro conditions, allowing researchers to study disease mechanisms and evaluate the efficacy and safety of novel therapies while reducing reliance on animal models.

This technology supports multiple areas of biomedical and translational research:

• Regenerative medicine & tissue engineering — fabrication of structures supporting regeneration of skin, cartilage, and bone
• Drug discovery and toxicology testing — more predictive evaluation of therapeutic efficacy and safety
• Personalized medicine — development of patient-specific disease models for individualized therapy testing
• Transplantology — long-term potential to fabricate transplantable organs using patient-derived cells, helping address donor organ shortages
• Improved predictability of preclinical studies

Bioinks are biological materials used to print living tissue constructs containing viable cells. They may be derived from natural components (e.g., collagen, gelatin) or synthetic polymers (e.g., PEG), and their composition is engineered according to the intended application.

Bioink parameters — including viscosity, chemical composition, cell density, and mechanical properties — directly influence:

• cell viability
• proliferation and differentiation
• structural integrity and mechanical stability
• accuracy of tissue architecture replication

Precise bioink optimization for specific research or clinical applications is critical to maintaining cellular functionality and ensuring long-term construct durability.

3D bioprinters are specialized devices designed to fabricate living tissue structures by depositing cell-laden hydrogels and biocompatible materials while preserving cell viability and function.

Three primary bioprinting technologies are used:

• Inkjet bioprinting
• Extrusion-based bioprinting
• Laser-assisted bioprinting

These methods differ in printing resolution, supported cell density, fabrication speed, and compatibility with specific bioinks. Process parameters must be carefully controlled, as excessive pressure, temperature fluctuations, or shear stress can compromise cell integrity.

Biomaterials and bioinks developed by Polbionica are compatible with leading 3D bioprinter manufacturers, including: Allevi, Aspect Biosystems (RX), CELLINK (BIO X), REGEMAT 3D (BIO V1), RegenHU (R-GEN), TissueLabs (TissueStart).

Advancements in 3D bioprinting are focused on fabricating functional, vascularized tissue structures with future applications in transplantation.

One of the greatest scientific challenges remains the recreation of vascular networks essential for long-term tissue survival and physiological function.

Key development directions include:

• bioprinting complex organoids and disease models
• high-cell-density bioinks
• microvascular fabrication technologies
• integration with real-time imaging and monitoring systems
• manufacturing standardization for clinical-grade applications

These breakthrough solutions are being developed by the interdisciplinary team at Polbionica.